Tesamorelin (30 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Tesamorelin (research code TH9507) is a stabilised analog of human growth-hormone-releasing hormone (GHRH) studied for its effect on visceral fat and the growth-hormone/IGF-1 axis. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published trials, not a recommendation for use in humans or animals.

For a 30 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of 10 mg/mL (10,000 mcg/mL). At that concentration, every 0.10 mL drawn on a U-100 insulin syringe equals 10 units and delivers 1 mg of material, which keeps the arithmetic clean across the daily titration steps.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the labelled clinical approach, where a reduced opening dose is held for the first week before stepping up to the full maintenance amount used throughout the published trial programs.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (10 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Daily Maintenance) Schedule

The labelled program does not use a high-dose escalation arm; instead it settles on a single fixed maintenance amount once tolerability is established. The table below reflects how that steady-state daily dose maps onto a 30 mg fill across an extended research run.

Supplies Needed

• Tesamorelin vials (30 mg): ~4 vials for an 8-week run (≈105 mg); ~6 vials for 12 weeks (≈161 mg); ~8 vials for 16 weeks (≈217 mg).
• Insulin syringes (U-100, 1 mL): ~56 for 8 weeks, ~84 for 12 weeks, ~112 for 16 weeks (one fresh syringe per daily draw).
• Bacteriostatic water (10 mL): 2 bottles for an 8–12 week run; 3 bottles for a 16-week run (3 mL per vial).
• Alcohol swabs: two 100-count boxes cover an 8–12 week schedule; three boxes for 16 weeks.

Protocol Overview

• Research goal: model reduction of visceral adipose tissue via pulsatile GHRH-driven growth-hormone release.
• Schedule: once-daily subcutaneous administration, typically modelled in the evening.
• Dose band: 1 mg lead-in (week 1), 2 mg daily maintenance thereafter.
• Fill: 30 mg lyophilized, reconstituted to 10 mg/mL with 3 mL diluent.
• Storage: 2–8 °C dry and 2–8 °C reconstituted (use within 7 days).

Dosing Protocol Notes

• Hold the 1 mg lead-in for the first week before stepping to the 2 mg maintenance dose.
• Keep administration on a fixed daily cadence — same time each day — for steady exposure modelling.
• Evening dosing is used in the labelled program to align with the natural overnight growth-hormone pulse.
• Continuous daily dosing is required; the visceral-fat effect reverses when administration stops.

Storage Instructions

Keep sealed lyophilized vials refrigerated at 2–8 °C (35.6–46.4 °F), protected from light; some newer formulations remain stable at 20–25 °C (68–77 °F) before reconstitution. Once reconstituted with bacteriostatic water, refrigerate at 2–8 °C and use within about seven days. Do not freeze the reconstituted solution and avoid repeated freeze-thaw cycles. If sterile (non-bacteriostatic) water is used, the solution should be used immediately and any unused portion discarded.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• Allow refrigerated solution to warm slightly before drawing to improve measurement accuracy.
• Document each draw — date, volume, remaining material — for reproducibility.

How Tesamorelin Works

Tesamorelin is a synthetic analog of human growth-hormone-releasing hormone (GHRH) modified with a trans-3-hexenoyl group that protects it from enzymatic degradation and extends its half-life. It binds GHRH receptors on the anterior pituitary and stimulates the gland to release growth hormone in its natural pulsatile pattern, which in turn raises circulating IGF-1. The downstream effect modelled in the literature is increased lipolysis — particularly within visceral adipose tissue — alongside shifts in protein synthesis and lipid handling. Because it amplifies the body's own GH axis rather than supplying exogenous growth hormone, the pulsatile profile is preserved.

Reported Benefits & Side Effects

Benefits observed in trials

• Significant reduction in visceral adipose tissue over a 3–6 month course.
• Improved lipid profiles and signals of reduced liver fat in non-alcoholic fatty-liver contexts.
• Reported gains in cognitive function among older study participants.
• Generally well tolerated, with benefits maintained through up to 52 weeks of continuous dosing.

Side effects reported

• Injection-site reactions — redness, itching, pain or bruising.
• Musculoskeletal symptoms such as joint pain, muscle aches and peripheral edema.
• Carpal-tunnel-type tingling or numbness, generally reversible.
• Small increases in HbA1c in some participants, warranting metabolic monitoring; not modelled in active malignancy or pregnancy.

Supporting Lifestyle Factors (Research Context)

• Protein-forward, balanced nutrition that supports the GH/IGF-1 anabolic signal in the study designs.
• Combined resistance and aerobic activity to maximise the modelled fat-loss effect.
• Seven to nine hours of quality sleep to align with natural overnight GH pulsatility.
• Stress management and consistent adherence as standard trial controls.

Injection Technique (Reference Only)

• Clean the vial stopper and the site with alcohol swabs and let them air-dry.
• Pinch a skinfold (abdomen, at least two inches from the navel, is the modelled site) and insert subcutaneously at 90° where fat is adequate or 45° on leaner tissue.
• Release the pinch, inject slowly, and pause 2–3 seconds before withdrawing the needle.
• Rotate sites systematically across the abdomen, thighs and upper arms, and dispose of sharps in an approved container.

References

Related Protocols